01—Abstract
Summary
Summary of the 10-Q filed July 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported second-quarter 2025 revenue, net of $603.3 milliona, up from $528.1 million in the prior-year quarter, and net income of $90.3 million versus $88.4 million.
For the six months ended June 30, 2025, revenue was $1.16 billionb and net income was $204.9 million. Growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas. Backlog was $2,873.6 million as of June 30, 2025, a decrease of $51.3 million, or 1.8%, from $2,924.9 million a year earlier.
Net new business awards were $620.5 millionc for the quarter and $1,120.6 million for the six months. The balance sheet changed significantly in 2025 because of share repurchases. Cash and cash equivalents fell to $46.3 million at June 30, 2025 from $669.4 million at December 31, 2024.
The company repurchased $908.4 milliond of stock in the first half of 2025 and had $826.3 million of remaining authorization at quarter-end. Total shareholders' equity declined to $172.4 million from $825.5 million, and the accumulated deficit reached $703.2 million. The company had no indebtedness at quarter-end.
In July 2025 it amended its credit facility to reduce the borrowing limit from $600.0 million to $10.0 million. Profitability was supported by a higher effective tax rate in the quarter of 27.5%, compared with 20.0% a year earlier. Operating cash flow for the six months was $274.4 million.
Direct costs and SG&A rose with the growth in service activity, and SG&A for the six months increased 22.2%. The filing also notes that the One Big Beautiful Bill Act was enacted on July 4, 2025, and that management is assessing its impact on the financial statements.
02—Key points
Key Highlights
- Q2 2025 revenue, net was $603.3 million, up from $528.1 million in Q2 2024; six-month revenue was $1,161.9 million versus $1,039.1 million.
- Q2 2025 net income was $90.3 million ($3.10 diluted EPS) versus $88.4 million ($2.75 diluted EPS) a year earlier.
- Backlog was $2,873.6 million at June 30, 2025, down 1.8% from $2,924.9 million a year earlier; net new business awards were $620.5 million for the quarter.
- The company repurchased $908.4 million of common stock in the first half of 2025, leaving $826.3 million of authorization remaining.
- Cash and cash equivalents declined to $46.3 million from $669.4 million at December 31, 2024, and total shareholders' equity fell to $172.4 million from $825.5 million.
- The company had no indebtedness at June 30, 2025; in July 2025 the credit facility was amended to a $10.0 million maximum borrowing amount from $600.0 million.
- The Q2 2025 effective tax rate was 27.5%, compared with 20.0% in Q2 2024.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 22, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $603.31M$528.10M | +14.2% |
| SG&A Expenses | $46.66M$41.45M | +12.6% |
| Operating Expenses | $476.98M$422.95M | +12.8% |
| Operating Income | $126.33M$105.15M | +20.1% |
| Net Income | $90.26M$88.35M | +2.2% |
| EPS (Basic) | $3.16$2.85 | +10.9% |
| EPS (Diluted) | $3.10$2.75 | +12.7% |
| Shares Outstanding (Basic) | 28.60M30.99M | −7.7% |
| Shares Outstanding (Diluted) | 29.14M32.09M | −9.2% |
05—Questions
Frequently Asked Questions
How did Medpace perform in the second quarter of 2025?
Revenue, net rose to $603.3 million from $528.1 million, and net income rose to $90.3 million from $88.4 million. Growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas.
Why did cash and shareholders' equity fall so sharply?
The company repurchased $908.4 million of its stock during the first six months of 2025, which reduced cash to $46.3 million and shareholders' equity to $172.4 million. Retired share repurchase amounts paid in excess of par value were charged to accumulated deficit/retained earnings.
What is the company's backlog and new business position?
Backlog was $2,873.6 million as of June 30, 2025, down $51.3 million, or 1.8%, from a year earlier. Net new business awards were $620.5 million for the quarter and $1,120.6 million for the six months. Approximately $1,740.0 million to $1,760.0 million of backlog is expected to convert to net revenue over the next twelve months.
Does Medpace have debt, and what changed in its credit facility?
As of June 30, 2025, the company had no indebtedness. The credit facility had $600.0 million available for borrowing at quarter-end, but on July 17, 2025 Amendment No. 9 reduced the maximum principal amount that may be borrowed to $10.0 million.
What tax and regulatory developments affect future results?
The effective tax rate was 27.5% for Q2 2025, up from 20.0%, mainly due to higher pre-tax income and a decrease in estimated FDII tax benefits. The One Big Beautiful Bill Act was enacted on July 4, 2025, and management is currently assessing its impact on the financial statements.
06—Continue